Related references
Note: Only part of the references are listed.Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
Amelie Clementine Seghers et al.
MELANOMA RESEARCH (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease
Adina Vultur et al.
CLINICAL CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Receptor tyrosine kinases and their activation in melanoma
David J. Easty et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Share Paper
